Vericel Revenue Growth Rates (VCEL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vericel Corporation  (NASDAQ: VCEL)
 

VCEL's Revenue Growth by Quarter and Year

Vericel's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VCEL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 77.46
1st Quarter March 68.43
FY 145.89

VCELs Annual Revenue
Vericel's Revenue in the fiscal year 2025 $ 276.26 millions
Vericel's Revenue in the fiscal year 2024 $ 237.22 millions
Vericel's Revenue in the fiscal year 2023 $ 197.52 millions
Vericel's Revenue in the fiscal year 2022 $ 164.37 millions
Vericel's Revenue in the fiscal year 2021 $ 156.18 millions




VCEL Revenue second quarter 2026 Y/Y Growth Comment
Vericel Corporation achieved in the second quarter 2026, above Company average Revenue growth of 22.48% year on year, to $ 77.46 millions.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 34 other companies have achieved higher Revenue growth. While Vericel Corporation' s Revenue rise of 22.48% ranks overall at the positon no. 2139 in the second quarter 2026.


VCEL Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 23.27 % 15.97 % 23.36 %
3rd Quarter September - 16.56 % 27.05 % 18.24 %
2nd Quarter June 22.48 % 20.09 % 14.68 % 23.94 %
1st Quarter March 30.1 % 2.57 % 25.01 % 13.72 %
FY   - 16.45 % 20.1 % -

Financial Statements
Vericel's second quarter 2026 Revenue $ 77.46 millions VCEL's Income Statement
Vericel's second quarter 2025 Revenue $ 63.24 millions Quarterly VCEL's Income Statement


VCEL Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 37.66 % 30.17 % 42.61 %
3rd Quarter September - 6.74 % 9.97 % -0.74 %
2nd Quarter June 13.19 % 20.23 % 2.69 % 11.95 %
1st Quarter March -26.36 % -30.22 % -21.11 % -22.15 %
FY (Year on Year)   - 16.45 % 20.1 % -


Back to VCEL Growth rate Comparisons >> Back to VCEL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #35
Healthcare Sector #317
Overall #2139

Revenue Y/Y Growth Statistics
High Average Low
42.13 % 19.01 % 2.4 %
(Dec 31 2018)   (Jun 30 2022)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #35
Healthcare Sector #317
Overall #2139
Revenue Y/Y Growth Statistics
High Average Low
42.13 % 19.01 % 2.4 %
(Dec 31 2018)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Vericel's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
117.92 % -1.71 % -100 %
(Sep 30 2014)  


VCEL's II. Quarter Q/Q Revenue Comment
Vericel Corporation achieved in the II. Quarter 2026 above company average sequential Revenue rise of 13.19%, to $ 77.46 millions, from $68.43 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Vericel's Revenue growth quarter on quarter, overall rank is 698.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #117
Overall #698
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #117
Overall #698
Revenue Q/Q Growth Statistics
High Average Low
117.92 % -1.71 % -100 %
(Sep 30 2014)  


VCEL's II. Quarter Q/Q Revenue Comment
Vericel Corporation achieved in the II. Quarter 2026 above company average sequential Revenue rise of 13.19%, to $ 77.46 millions, from $68.43 millions in the first quarter.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Vericel's Revenue growth quarter on quarter, overall rank is 698.


Vericel's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 306.30 $ 292.09 $ 276.26 $ 258.72 $ 249.12
Y / Y Revenue Growth (TTM) 22.95 % 22.45 % 16.45 % 14.05 % 16.13 %
Year on Year Revenue Growth Overall Ranking # 1056 # 903 # 383 # 497 # 556
Seqeuential Revenue Change (TTM) 4.87 % 5.73 % 6.78 % 3.85 % 4.43 %
Seq. Revenue Growth (TTM) Overall Ranking # 2144 # 2166 # 1249 # 1465 # 1752


Cumulative Revenue growth Comment
Vericel saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 22.95% year on year, to $ 306 millions if the fiscal year would have ended in Jun 30 2026.
Vericel's trailing twelve months Revenue growth was higher than company's average 19.01% and higher than 22.45% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 4.87 % from $292.09 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at19.01%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 4.87 % increase from $292.09 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 203 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 903 to 1056.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 35
Healthcare Sector # 204
Overall # 1056

Revenue TTM Y/Y Growth Statistics
High Average Low
42.13 %
 19.01 %
2.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 317
S&P 500 # 2144
Cumulative Revenue growth Comment
Vericel saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 22.95% year on year, to $ 306 millions if the fiscal year would have ended in Jun 30 2026.
Vericel's trailing twelve months Revenue growth was higher than company's average 19.01% and higher than 22.45% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 4.87 % from $292.09 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at19.01%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 4.87 % increase from $292.09 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 203 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 903 to 1056.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 35
Healthcare Sector # 204
Overall # 1056

Revenue TTM Y/Y Growth Statistics
High Average Low
42.13 %
19.01 %
2.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 317
S&P 500 # 2144




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VCEL's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions
Corcept Therapeutics Inc31.74%$ 31.743 millions
Establishment Labs Holdings Inc 31.73%$ 31.733 millions
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions


About Vericel Revenue Growth Rates (VCEL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vericel Corp (CIK 887359).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-050836
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vericel Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.